Obstetrics/Gynecology
RSSArticles
-
Options Expand for Women: FDA Approves a New Intrauterine Device
A new option in intrauterine contraception has been approved: the LILETTA intrauterine device.
-
Farewell and Welcome
Dr. Robert Coleman, a member of the editorial board of OB/GYN Clinical Alert since 2004, has been elected as the next President of the Society of Gynecologic Oncologists.
-
Postoperative Delirium in Older Adults
The elderly operative patient has very different and specific needs compared to a younger woman. In addition to a higher risk of medical comorbidities, elderly women are affected by cognitive impairment, depression, gait, and balance disturbances.
-
NIPT and Invasive Procedures
A single prenatal testing center with a large volume of patients has experienced a dramatic drop in the rate of chorionic villus sampling and amniocentesis after the introduction of noninvasive prenatal testing.
-
Hormonal Contraception and Glioma: Is There Reason for Concern?
A large case-control study using the Danish National database found a slight increase in the risk of glioma in ever-users of hormonal contraception, which increased with duration of use. Users of progestin-only methods were at higher risk. However, these findings should not influence clinical practice or perception of contraceptive safety.
-
Finding New Clinical Activity in Endometrial Cancer from Optimizing Molecular Pathways
Everolimus, combined with letrozole, produced unexpected clinical activity in a cohort of previously treated recurrent endometrial cancer patients.
-
HPV screening: Option to cytology-based options
Primary human papillomavirus (HPV) screening can be considered as an alternative to current U.S. cytology-based cervical cancer screening methods, according to new interim guidance from the Society of Gynecologic Oncology and the American Society for Colposcopy and Cervical Pathology.1
-
Data reaffirm the effectiveness of LNG, copper intrauterine devices
Findings from a recent analysis of data from a large, multi-country study of women using levonorgestrel or copper intrauterine devices (IUDs) indicate that while both forms of contraception have high levels of efficacy, the levonorgestrel device daily releasing 20 mcg (Mirena LNG IUD, Bayer Healthcare Pharmaceuticals, Wayne, NJ) was associated with a significantly lower risk of pregnancy, including ectopic pregnancy, than copper IUDs.1
-
New HPV vaccine covers 9 types of HPV
Get ready to include a new human papillomavirus (HPV) vaccine at your facility. The Food and Drug Administration (FDA) has approved Gardasil 9 from Kenilworth, NJ-based Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
-
Some groups continue to bear disproportionate burden of STIs
While the latest national surveillance data show signs of progress in reducing chlamydia and gonorrhea among young people ages 15-24, the numbers and rates of reported cases of these two diseases continue to be highest in this group compared to other age groups.1